Alzamend Neuro, Inc.ALZNNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank0
Year-over-Year Change

Year-over-year research & development expense growth

Percentile
P0
Near historical low
vs 3Y Ago
-0.3x
Contraction
Streak
3 yr
Consecutive declineDecelerating
PeriodValue
2025-78.08%
2024-13.31%
202343.16%
2022296.72%
202122.64%
2020-71.11%
20191044.08%
201817.58%
20170.00%
20160.00%